Ernexa Therapeutics (NASDAQ: ERNA) announced positive preliminary preclinical results for ERNA-201, its synthetic allogeneic induced mesenchymal stem cell (iMSC) therapy ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE